Welcome to our dedicated page for Zhengye Biotechnology Holding SEC filings (Ticker: ZYBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zhengye Biotechnology Holding Limited (ZYBT) SEC filings page provides access to the company’s U.S. regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. Zhengye Biotechnology files registration and periodic reports with the U.S. Securities and Exchange Commission in connection with its veterinary vaccine business, which focuses on research, development, manufacturing, and sales of vaccines for livestock and other animals.
Key documents for ZYBT include its registration statement on Form F-1, which supported the company’s initial public offering of ordinary shares, and its annual report on Form 20-F, which contains audited financial statements, risk factors, and detailed information about its veterinary vaccine operations in China and abroad. The company also furnishes Form 6-K reports, such as unaudited interim financial statements and management’s discussion and analysis for periods like the six months ended June 30, 2025.
Through this page, users can review how Zhengye Biotechnology reports revenue from swine, poultry, and other vaccines, as well as disclosures on operating expenses, R&D spending, and balance sheet items. Filings may also describe regulatory developments, including Category I New Veterinary Drug approvals granted by the Ministry of Agriculture and Rural Affairs for jointly developed vaccines, and provide context on the company’s geographic reach across China and exports to Vietnam, Pakistan, and Egypt.
Stock Titan enhances these filings with AI-powered summaries that explain complex sections in plain language, highlight key changes from prior periods, and surface notable items such as liquidity trends or customer concentration. Users can quickly scan annual Form 20-F reports, interim Form 6-K updates, and offering-related documents without reading every page, while still having direct access to the full text from EDGAR for deeper analysis.
Zhengye Biotechnology Holding Limited filed a Form 6-K as a foreign private issuer, furnishing unaudited consolidated financial statements and notes for the six months ended June 30, 2025. The exhibits also include unaudited consolidated financial statements and notes for the six months ended June 30, 2025 and 2024, together with management’s discussion and analysis of financial condition and results of operations for the same interim period. Related Inline XBRL instance and taxonomy extension files are provided to present the financial data in structured electronic format.
Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) filed its first Form 20-F as a foreign private issuer for the fiscal year ended 31 Dec 2024. The Cayman-incorporated holding company owns Chinese operating subsidiaries engaged in animal-health vaccines and related biological products. At year-end the company had 45,666,376 ordinary shares outstanding and reports under U.S. GAAP; it is classified as a non-accelerated filer and emerging-growth company.
The filing contains extensive disclosures on legal and operational risks of operating almost entirely in mainland China. Key themes include:
- Regulatory filings completed: the company has filed and received CSRC approval (8 Jan 2024) for its overseas listing and believes it is currently below thresholds that would trigger CAC cybersecurity or SAMR anti-monopoly reviews.
- Government oversight risk: PRC authorities may intervene in, or impose new rules on, data security, anti-monopoly, biotechnology or foreign listings, potentially causing material changes in operations or rendering ZYBT shares “worthless.”
- HFCA Act exposure: while auditor WWC, P.C. is PCAOB-inspected, future access disputes could lead to trading prohibitions after two consecutive years of blocked inspection, per the amended HFCA Act.
- Cross-border cash-flow limits: dividend payments from PRC subsidiaries are restricted by SAFE rules, statutory reserve requirements and possible future capital-control tightening; similar uncertainties apply to Hong Kong.
- Structural considerations: investors purchase Cayman equity and have no direct ownership in PRC subsidiaries. The group currently operates without a VIE structure but acknowledges Chinese regulators could still disallow the holding-company arrangement.
- Business-specific risks: heavy reliance on swine-vaccine revenue, limited raw-material suppliers, high customer concentration, product-liability exposure and increasing labor costs in China.
No audited financial statements or performance metrics are included in the excerpt provided, so profitability and liquidity cannot be assessed here. Overall, the 20-F emphasizes compliance progress but highlights pervasive regulatory, geopolitical and operational uncertainties that could materially impact valuation and market access.